Evofem Biosciences Inc (EVFM)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Saundra L. Pelletier
Employees:
120
12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA 92130
(858) 550-1900

Evofem Biosciences, Inc. develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy.

Data derived from most recent annual or quarterly report
Market Cap 68.162 Million Shares Outstanding142.598 Million Avg 30-day Volume 23.054 Million
P/E Ratio0.0 Dividend Yield0.0 EPS1.09
Price to Revenue1.9694 Debt to Equity-0.5533 EBITDA-282.395 Million
Price to Book Value0.0 Operating Margin-861.6625000000001 Enterprise Value128.7 Million
Current Ratio0.158 EPS Growth0.42 Quick Ratio0.102
1 Yr BETA 0.9779 52-week High/Low 14.61 / 0.28 Profit Margin-1821.0509
Operating Cash Flow Growth34.8143 Altman Z-Score-48.8536 Free Cash Flow to Firm 41.431 Million
View SEC Filings from EVFM instead.

View recent insider trading info

Evofem Biosciences Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding EVFM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EVFM

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2022-08-08 by YIP JENNY C.
  • 3: filed on 2022-06-07 by ATKINSON KATHERINE COCCA
  • 4: filed on 2022-05-31 by PELLETIER SAUNDRA L
  • 4: filed on 2022-05-06 by O'BRIEN ANTHONY STEPHEN
  • 4: filed on 2022-05-06 by KAMDAR KIM P.
  • 4: filed on 2022-05-06 by RUTHERFORD COLIN
  • 4: filed on 2022-05-06 by RARICK LISA DALE
  • 4: filed on 2022-05-06 by GREER GILLIAN
  • 4: filed on 2022-02-23 by FITZPATRICK ALEXANDER A
  • 4: filed on 2022-02-23 by FILE JUSTIN J.

    • Events (8k)

  • 8-K: filed on 2023-03-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-21:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
  • 8-K: filed on 2023-03-17:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-03-14:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
  • 8-K: filed on 2023-03-10:
    Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-03-09:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-02-24:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-23:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-01-12:
    Item 8.01: Other Events

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    YIP JENNY C.

    • Director
    		 0 2022-08-02 1

    ATKINSON KATHERINE COCCA CHIEF COMMERCIAL OFFICER

    • Officer
    		 16,667 2022-05-31 1

    PELLETIER SAUNDRA L CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 236,722 2022-05-27 1

    KAMDAR KIM P.

    • Director
    		 6,000 2022-05-04 1

    GREER GILLIAN

    • Director
    		 6,000 2022-05-04 1

    RUTHERFORD COLIN

    • Director
    		 6,000 2022-05-04 1

    O'BRIEN ANTHONY STEPHEN

    • Director
    		 6,000 2022-05-04 1

    RARICK LISA DALE

    • Director
    		 6,000 2022-05-04 1

    FITZPATRICK ALEXANDER A GENERAL COUNSEL AND SECRETARY

    • Officer
    		 816,422 2022-02-18 0

    FILE JUSTIN J. CHIEF FINANCIAL OFFICER

    • Officer
    		 1,260,982 2022-02-18 0

    BARRANS RUSSELL CHIEF COMMERCIAL OFFICER

    • Officer
    		 448,833 2021-07-08 0

    CULWELL KELLY CHIEF MEDICAL OFFICER

    • Officer
    		 273,390 2021-05-20 0

    HALL WILLIAM WALMSLEY

    • Director
    		 90,000 2021-05-12 0

    ACACIA RESEARCH CORP

    • 10% Owner
    		 9,139,504 2020-06-04 0

    LINK FUND SOLUTIONS LTD

    • 10% Owner
    		 0 2020-06-04 0

    PDL BIOPHARMA, INC.

    • 10% Owner
    		 No longer subject to file 2020-05-21 0

    INVESCO LTD.

    • 10% Owner
    		 No longer subject to file 2020-05-14 0

    LYNCH THOMAS G

    • Director
    		 325,000 2020-03-31 0

    MONNET DOMINIQUE

    • Director
    		 0 2019-06-10 0

    KNUDSON SUSAN A. CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2017-06-22 0

    FELDMAN MARIA VP, CLINICAL RESEARCH

    • Officer
    		 0 2017-06-22 0

    DEMSKI MARTHA J

    • Director
    		 0 2017-06-20 0

    NUGENT JEFFREY M

    • Director
    		 0 2017-06-20 0

    GORBACHEV MAXIM

    • Director
    		 0 2017-06-20 0

    LOCKE KENNETH W CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2016-02-04 0

    ALTA PARTNERS VIII, L.P.

    ALTA PARTNERS MANAGEMENT VIII, LLC

    CHAMPSI FARAH

    JANNEY DANIEL

    NOHRA GUY P

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    		 No longer subject to file 2015-12-28 0

    MAHAFFEY GEORGE W PRESIDENT AND CEO

    • Officer
    • Director
    		 171,040 2015-10-15 0

    ZEINI HANI M

    • Director
    		 0 2015-09-23 0

    KEMMERER CHRISTOPHER VP, PHARMA DEV & MANUFACTURING

    • Officer
    		 10,848 2015-09-18 0

    JANNEY DANIEL

    • Director
    • 10% Owner
    		 0 2015-06-16 0

    KROCHMAL LINCOLN CHIEF MEDICAL OFFICER

    • Officer
    		 0 2015-02-10 0

    SHAH NIMESH

    • 10% Owner
    		 3,934 2015-01-01 0

    DP VII ASSOCIATES LP

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    HALAK BRIAN K

    • 10% Owner
    		 48,025 2014-11-25 0

    DOMAIN PARTERS VII L P

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    HALAK BRIAN K

    • 10% Owner
    		 3,091,643 2014-11-25 0

    RMI INVESTMENTS S.A.R.L.

    RUSNANOMEDINVEST LLC

    • 10% Owner
    		 1,585,549 2014-11-25 0

    DOMAIN ASSOCIATES

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    HALAK BRIAN K

    KAMDAR KIM P.

    • Director
    • 10% Owner
    		 3,934 2014-11-19 0

    WALKER PATRICIA S

    • Director
    		 0 2014-11-19 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 22:15:04 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 21:45:05 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 21:15:03 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 20:45:04 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 20:15:04 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 19:45:04 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 19:15:04 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 18:45:04 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 18:15:04 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 17:45:04 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 17:15:03 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 16:45:04 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 16:15:04 UTC -48.2843 53.1043 3900000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 15:45:04 UTC -48.2843 53.1043 3700000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 15:15:03 UTC -48.2843 53.1043 3700000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 14:45:04 UTC -48.2843 53.1043 3700000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 14:15:04 UTC -48.2843 53.1043 3700000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 13:45:03 UTC -48.2843 53.1043 3700000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 13:15:03 UTC -48.2843 53.1043 3700000
    EVOFEM BIOSCIENCES INC EVFM 2023-03-31 12:45:03 UTC -48.2843 53.1043 3700000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments